PEDIATRICS Vol. 92 No. 1 July 1993, pp. 184-185
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by GALBRAITH, R. A.
Right arrow Articles by KAPPAS, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by GALBRAITH, R. A.
Right arrow Articles by KAPPAS, A.

More to Be Learned From Crigler-Najjar Patients

RICHARD A. GALBRAITH MD1, GEORGE S. DRUMMOND PHD1, and ATTALLAH KAPPAS MD1

1 The Rockefeller University Hospital, 1230 York Avenue, New York, NY 10021-6399

In Reply.—

We thank Dr Hansen for his comments on our study in Crigler-Najjar patients published recently in Pediatrics. A collaborative study of this rare genetic disease does seem in order as Dr Hansen indicates; to the extent that such a study might involve an examination of the efficacy of the heme oxygenase inhibitor tin-mesaporphyrin for ameliorating (with other therapeutic modalities) hyperbilirubinemia in this syndrome, we would be happy to collaborate with other investigators and to provide some resources for the study as required.